Company intelligence / Profile preview
BulBio-NCIPD
- Ownership
- Private
- Employees
- ~400
- Development stage
- Other
Overview
BulBio-NCIPD is a state-owned Bulgarian biotechnology company that serves as a major global manufacturer of vaccines and immunobiological products. Headquartered in Sofia, the company is the commercial successor to the production division of the National Center of Infectious and Parasitic Diseases, with roots dating back to 1881. BulBio-NCIPD is most notably one of the world's primary suppliers of the BCG vaccine, providing millions of doses annually to international health organizations like UNICEF and the WHO. Its extensive product portfolio also includes tetanus and diphtheria toxoids, polyvalent snake antivenoms, human immunoglobulins, and a variety of diagnostic reagents. The company operates modern, GMP-certified manufacturing facilities and plays a critical role in both national and international public health immunization strategies.
- Therapeutic areas
- OncologyImmunologyOtherInfectious Diseases
- Modalities
- VaccineBiologicAntibodyProtein
- Industry
- Biotech
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on BulBio-NCIPD.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BulBio-NCIPD.